ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Jul 26, 2023 3:17pm

151 Views

Post# 35558242

BEST IN CLASS / WORST ON THE MARKET

I am so sick of hearing about how good we are and this BOD mismanages the finances of this Company. Now you stated we must go on NASDAQ and that has been the worst decision. Now you have a new CEO and the stock has never seen these lows before, what gives brainiacs? Get your dam act together or get OUT!!!!!!!!!!!!! SICK OF THIS BS!!!!!!!!!!!

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec